The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury

Bibliography

• Leimgruber PP, Roubin GS, Hollman J, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986;73:710-7
   PubMed Web of Science ®Google Scholar
• Haude M, Konorza TF, Kalnins U, et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003;107:1265-70
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr. In-stent restenosis. Rev Cardiovasc Med 2001;2:115-9
   PubMedGoogle Scholar
• Danzi GB, Sesana M, Capuano C, et al. Restenosis after NIR stent implantation. Minerva Cardioangiol 2002;50:455-62
   PubMedGoogle Scholar
• Wilensky RL, March KL, Gradus-Pizlo I, et al. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 1995;92:2995-3005
   PubMedGoogle Scholar
• Austin GE, Ratliff NB, Hollman J, et al. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-75
   PubMed Web of Science ®Google Scholar
• Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403-9
   PubMed Web of Science ®Google Scholar
• Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 2005;59:102-6
   PubMedGoogle Scholar
• Leik CE, Su EJ, Nambi P, et al. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006;4:2710-5
   PubMed Web of Science ®Google Scholar
• Ibarra CA, Blouse GE, Christian TD, Shore JD. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. J Biol Chem 2004;279:3643-50
   PubMed Web of Science ®Google Scholar
• Crandall DL, Elokdah H, Di L, et al. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in vivo efficacy. J Thromb Haemost 2004;2:1422-8
   PubMed Web of Science ®Google Scholar
• Liang A, Wu F, Tran K, et al. Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res 2005;115:341-50
   PubMedGoogle Scholar
• Peters RF, Lees CM, Mitchell KA, et al. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb Haemost 1991;65:268-74
   PubMedGoogle Scholar
• Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993;73:792-6
   PubMed Web of Science ®Google Scholar
• Suzuki J, Izawa A, Isobe M. Anti-vascular cell adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies inhibit neointimal hyperplasia in the murine model of arterial injury. Acuta Cardiologica 2004;59:147-52
   PubMed Web of Science ®Google Scholar
• Suzuki J, Morishita R, Amano J, et al. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 2000;7:1847-52
   PubMedGoogle Scholar
• Suzuki J, Cole SE, Batirel S, et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 2003;3:968-76
   PubMed Web of Science ®Google Scholar
• DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 2001;104:1972-81
   PubMed Web of Science ®Google Scholar
• Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33
   PubMed Web of Science ®Google Scholar
• Maejima Y, Adachi S, Ito H, et al. Nitric oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulating cyclin A-associated kinase activity. Cardiovasc Res 2003;59:308-20
   PubMed Web of Science ®Google Scholar
• Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007
   PubMed Web of Science ®Google Scholar
• Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-904
   PubMed Web of Science ®Google Scholar
• Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63
   PubMed Web of Science ®Google Scholar
• Huber K, Jörg M, Probst P, et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992;67:209-13
   PubMed Web of Science ®Google Scholar
• Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998-7002
   PubMed Web of Science ®Google Scholar
• Kauhanen P, Sirén V, Carpén O, et al. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Circulation 1997;96:1783-9
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997;96:3180-91
   PubMed Web of Science ®Google Scholar
• Hennan JK, Elokdah H, Leal M, et al. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 2005;314:710-6
   PubMed Web of Science ®Google Scholar
• Weisberg AD, Albornoz F, Griffin JP, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005;25:365-71
   PubMed Web of Science ®Google Scholar
• Smith LH, Dixon JD, Stringham JR, et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006;107:132-4
   PubMed Web of Science ®Google Scholar
• Waltz DA, Natkin LR, Fujita RM, et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100:58-67
   PubMed Web of Science ®Google Scholar
• Bajou K, Noël A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-8
   PubMed Web of Science ®Google Scholar
• Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 1996;383:441-3
   PubMed Web of Science ®Google Scholar
• Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopathology 2007;50:535-46
   PubMed Web of Science ®Google Scholar
• Harja E, Bucciarelli LG, Lu Y, et al. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res 2004;94:333-9
   PubMed Web of Science ®Google Scholar
• Xiao Q, Danton MJ, Witte DP, et al. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest 1998;101:1184-94
   PubMedGoogle Scholar
• Varenne O, Sinnaeve P, Gillijns H, et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum Gene Ther 2000;11:1329-39
   PubMedGoogle Scholar
• Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. Circ Res 1997;80:490-6
   PubMedGoogle Scholar
• Hasenstab D, Lea H, Clowes AW. Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler Thromb Vasc Biol 2000;20:853-9
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Dewerchin M, Lijnen HR, et al. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 2000;96:153-60
   PubMedGoogle Scholar
• Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998;97:1002-8
   PubMed Web of Science ®Google Scholar
• Chen Y, Kelm RJJ, Budd RC, et al. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 2004;92:178-88
   PubMed Web of Science ®Google Scholar
• Chen Y, Budd RC, Kelm RJ Jr, et al. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 2006;26:1777-83
   PubMed Web of Science ®Google Scholar
• Schafer K, Konstantinides S. PAI-1 and vasculopathy: the debate continues. J Thromb Haemost 2004;2:13-5
   PubMedGoogle Scholar
• Lijnen HR, Van Hoef B, Umans K, Collen D. Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost 2004;2:16-22
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Hayes M, Wadsworth M, et al. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1). J Histochem Cytochem 2004;52:1091-9
   PubMedGoogle Scholar
• Schafer K, Schroeter MR, Dellas C, et al. Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol 2006;26:1254-9
   PubMedGoogle Scholar